These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 10719543)

  • 1. [New developments in the treatment of diabetic foot ulcers].
    Bakker K; Schaper NC
    Ned Tijdschr Geneeskd; 2000 Feb; 144(9):409-12. PubMed ID: 10719543
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Growth factors in the treatment of diabetic foot ulcers: new technologies, any promises?
    Papanas N; Maltezos E
    Int J Low Extrem Wounds; 2007 Mar; 6(1):37-53. PubMed ID: 17344201
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The nitric oxide connection: hyperbaric oxygen therapy, becaplermin, and diabetic ulcer management.
    Boykin JV
    Adv Skin Wound Care; 2000; 13(4 Pt 1):169-74. PubMed ID: 11075012
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New treatments in ulcer healing and wound infection.
    Edmonds M; Bates M; Doxford M; Gough A; Foster A
    Diabetes Metab Res Rev; 2000; 16 Suppl 1():S51-4. PubMed ID: 11054889
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systematic reviews of wound care management: (3) antimicrobial agents for chronic wounds; (4) diabetic foot ulceration.
    O'Meara S; Cullum N; Majid M; Sheldon T
    Health Technol Assess; 2000; 4(21):1-237. PubMed ID: 11074391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of topical recombinant human platelet-derived growth factor-BB (becaplermin) in healing of chronic mixed arteriovenous lower extremity diabetic ulcers.
    Miller MS
    J Foot Ankle Surg; 1999; 38(3):227-31. PubMed ID: 10384364
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Approval for recombinant growth factor. Since January 2000, patients with diabetic foot ulcers can be treated with the growth factor becaplermin (Regranex), manufactured with genetic technology].
    Fruhstorfer B
    Internist (Berl); 2000 Jan; 41(1):A38. PubMed ID: 10712088
    [No Abstract]   [Full Text] [Related]  

  • 8. Recombinant human platelet-derived growth factor-BB (becaplermin) for healing chronic lower extremity diabetic ulcers: an open-label clinical evaluation of efficacy.
    Embil JM; Papp K; Sibbald G; Tousignant J; Smiell JM; Wong B; Lau CY
    Wound Repair Regen; 2000; 8(3):162-8. PubMed ID: 10886806
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor-BB (becaplermin) in patients with chronic neuropathic diabetic ulcers. A phase III randomized placebo-controlled double-blind study.
    Wieman TJ; Smiell JM; Su Y
    Diabetes Care; 1998 May; 21(5):822-7. PubMed ID: 9589248
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The future of recombinant growth factors in wound healing.
    Robson MC; Mustoe TA; Hunt TK
    Am J Surg; 1998 Aug; 176(2A Suppl):80S-82S. PubMed ID: 9777977
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Growth factors in the treatment of diabetic foot ulcers.
    Bennett SP; Griffiths GD; Schor AM; Leese GP; Schor SL
    Br J Surg; 2003 Feb; 90(2):133-46. PubMed ID: 12555288
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical evaluation of recombinant human platelet-derived growth factor for the treatment of lower extremity ulcers.
    Steed DL
    Plast Reconstr Surg; 2006 Jun; 117(7 Suppl):143S-149S; discussion 150S-151S. PubMed ID: 16799381
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advanced biological therapies for diabetic foot ulcers.
    Kirsner RS; Warriner R; Michela M; Stasik L; Freeman K
    Arch Dermatol; 2010 Aug; 146(8):857-62. PubMed ID: 20713816
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of becaplermin for nonhealing neuropathic diabetic foot ulcers.
    Sibbald RG; Torrance G; Hux M; Attard C; Milkovich N
    Ostomy Wound Manage; 2003 Nov; 49(11):76-84. PubMed ID: 14652415
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Which is the better option: recombinant human PDGF-BB 0.01% gel or standard wound care, in diabetic neuropathic large plantar ulcers off-loaded by a customized contact cast?
    Bhansali A; Venkatesh S; Dutta P; Dhillon MS; Das S; Agrawal A
    Diabetes Res Clin Pract; 2009 Jan; 83(1):e13-6. PubMed ID: 19081156
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost effectiveness of Becaplermin in the treatment of diabetic foot ulcers in four European countries.
    Ghatnekar O; Persson U; Willis M; Odegaard K
    Pharmacoeconomics; 2001; 19(7):767-78. PubMed ID: 11548912
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Becaplermin: recombinant platelet derived growth factor, a new treatment for healing diabetic foot ulcers.
    Nagai MK; Embil JM
    Expert Opin Biol Ther; 2002 Feb; 2(2):211-8. PubMed ID: 11849120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [News in the management of chronic neuropathic diabetic ulcer].
    Meaume S
    Soins; 2001 Jun; (656):12-3. PubMed ID: 12008527
    [No Abstract]   [Full Text] [Related]  

  • 19. Effective treatment strategies for diabetic foot wounds.
    Millington JT; Norris TW
    J Fam Pract; 2000 Nov; 49(11 Suppl):S40-8. PubMed ID: 11093557
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of Regranex gel for diabetic foot ulcers.
    Piascik P
    J Am Pharm Assoc (Wash); 1998; 38(5):628-30. PubMed ID: 9782698
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.